法玛新膀胱灌洗预防浅表性膀胱癌术后复发的临床观察  

Instillation of epirubicin for prevention of postoperative recurrence of superficial bladder cancer

作　　者：张宝刚[1] 田玉新[2] 王春喜[3] 

机构地区：[1]吉林大学中日联谊医院镜检科,吉林长春130033 [2]吉林省肿瘤医院泌尿外科,吉林长春130012 [3]吉林大学第一医院泌尿外科,吉林长春130021

出　　处：《吉林医学》2007年第11期1272-1273,共2页Jilin Medical Journal

摘　　要：目的：对法玛新膀胱灌洗预防浅表性膀胱癌术后复发进行临床疗效观察。方法：对52例浅表性膀胱癌患者进行随访,法玛新80mg术后6h内膀胱灌注,之后每3个月膀胱灌洗法玛新50mg 1次,2年为1个疗程。结果：随访时间12-24个月,平均16.8个月,共7例膀胱癌复发,1年复发率为9.6%（5/52）,2年复发率为18.1%（4/22）,不良反应发生情况共6例（11.6%）。结论：术后6h内大剂量膀胱灌注法玛新,之后每3个月膀胱灌洗法玛新1次,可以使浅表性膀胱肿瘤复发率明显降低,患者耐受性好、副反应发生率低。Objective To explore the efficiency and safety of instillation with epirubicin to prevent postoperative recurrence of superficial bladder cancer.Method 52 cases with superficial bladder cancer were enrolled in this study.The patients were instilled with epirubicin（80mg/40ml in normal saline） within 6 hours after transurethral resection or partial bladder removal.Thereafter the patients received intravesical instillations of epirubicin（50mg/40ml in normal saline） every 3 months to complete 2 years of treatment.Results The mean follow-up period was 16.8 months（ranged 12 -24 months）.The recurrence rate was 9.6%（5/52） at 1 year,and 18.1%（4/22） at 2 years after operation.The incidence of side effects was 11.6%（6/52）.Conclusion The above project is markedly effective for preventing the recurrence of superficial bladder tumors after surgical management and with mild side effects.This method has high clinical values.

关 键 词：膀胱肿瘤 表阿霉素 肿瘤复发 膀胱灌洗 

分 类 号：R737.14[医药卫生—肿瘤]